A double-blind randomized placebo-controlled study of Desvenlafaxine for managing vasomotor symptoms in breast cancer survivors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210326006

Enrollment

Registered

2021-03-26

Start date

2021-03-17

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasomotor symptoms Vasomotor symptoms

Interventions

Oral Desvenlafaxine 50 mg for 12 weeks,Oral placebo for 12 weeks

Placebo Comparator Drug,Placebo Comparator Drug

Desvenlafaxine,Placebo

Eligibility

Sex/Gender

Female

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Women, who were diagnosed breast cancer, have moderate to severe vasomotor symptoms

Exclusion criteria

Exclusion criteria: 1. Allergy to SSRI and SNRI 2. Hormonal treatment within 4 weeks prior 3. History of epilepsy 4. History of myocardial infarction within 6 months prior 5. History of depression, bipolar disease or psychological conditions 6. History of glaucoma or increased intraocular pressure 7. Malabsorption 8. Hypertension 9. Impaired liver or renal disease

Design outcomes

Primary

Measure	Time frame
Vasomotor symptoms 7 days, 4 weeks, 12 week Frequency of hot flashes, Greene Climacteric Scale	—

Secondary

Measure	Time frame
Adverse events 12 weeks after treatment Patient reported outcome using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactMaytha Sakulpaisal

OB-GYN

Maytha_may@hotmail.com0878805225

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026